tesamorelin body composition: Frequently asked questions

First verify injection technique and storage. Tesamorelin must be injected subcutaneously into abdominal fat using a 90-degree angle with a 5/16" to 1/2" needle. Intramuscular injection reduces absorption. Reconstituted vials stored above 8°C lose potency within 7–10 days; even brief temperature excursions during shipping can denature the peptide before you ever use it. If storage and technique are correct, the issue is likely insufficient baseline VAT. Patients starting below 80 cm² on CT imaging show minimal measurable change because there isn't enough visceral fat to mobilize. Consider DEXA or MRI imaging to confirm VAT volume before concluding the peptide isn't working.

Transient glucose elevation is expected during the first 8–12 weeks due to GH's counterregulatory effects on insulin signaling. Monitor fasting glucose weekly during this period. If fasting glucose rises above 110 mg/dL or HbA1c increases by >0.3%, consider pairing tesamorelin with metformin 500–1000mg daily to offset insulin resistance. Do not combine tesamorelin with exogenous insulin without endocrine oversight. The interaction amplifies hypoglycemia risk. Glucose elevations that persist beyond 12 weeks suggest impaired glucose tolerance predating tesamorelin use.

Joint pain (arthralgia) occurs in 12–15% of tesamorelin users and reflects elevated GH's effect on connective tissue hydration and cartilage metabolism. If pain persists beyond 6 weeks or worsens with continued use, reduce the dose to 1.5mg daily for 2 weeks before returning to 2mg. This allows GH receptor sensitivity to normalise. Persistent severe pain may indicate baseline joint pathology exacerbated by GH. In that case, discontinuation is warranted. Over-the-counter NSAIDs can manage mild symptoms during the adaptation phase.

Weight gain during tesamorelin treatment typically reflects lean mass accrual, not fat accumulation. Growth hormone stimulates protein synthesis and nitrogen retention, which can add 0.5–1.5 kg of muscle tissue across 26 weeks if you're resistance training consistently. This is desirable. Increased lean mass elevates resting metabolic rate by 30–50 calories per kilogram, compounding fat oxidation over time. Total body weight is a poor metric for tracking tesamorelin efficacy; waist circumference and imaging-based VAT measurements are the relevant endpoints.

Growth hormone levels return to baseline within 48–72 hours of the last tesamorelin dose, and IGF-1 begins declining within five days. Missing three consecutive injections eliminates the cumulative GH elevation that drives VAT mobilization. Resume injections immediately at your standard dose. Do not double-dose to compensate, as this won't recreate the pulsatile secretion pattern and increases side effect risk (joint pain, peripheral edema, glucose dysregulation). Extended gaps (seven days or more) during the first 12 weeks may require restarting the timeline from week zero, as lipolytic enzyme activity returns to baseline without sustained GH signaling.

First, verify baseline VAT levels via CT or MRI. Tesamorelin's efficacy is tied directly to the size of the existing visceral depot, and individuals with baseline VAT <80 cm² consistently show minimal response. If baseline VAT was high, check reconstitution and storage protocol. A single temperature excursion above 8°C during storage denatures the peptide entirely, rendering it ineffective despite appearing clear. Finally, confirm injection timing. Dosing more than 2 hours before sleep shifts GH release out of alignment with nocturnal pulse architecture, reducing efficacy by 30–40%.

Rotate injection sites more aggressively. Use a 6-site rotation pattern across lower abdominal quadrants and avoid injecting within 2 inches of any previous site for 72 hours. Mild erythema (redness) lasting 30–60 minutes post-injection is normal and reflects localised histamine release from subcutaneous mast cells. Persistent redness beyond 2 hours, swelling, or induration (hardened tissue) suggests either allergic sensitivity to the benzyl alcohol preservative in bacteriostatic water or lipohypertrophy from repeated injections at the same site. If symptoms persist despite rotation, switch to preservative-free sterile water for reconstitution. This reduces shelf life to 72 hours but eliminates preservative-related reactions.

Discard the vial immediately. Do not attempt to use it. Tesamorelin's peptide structure undergoes irreversible denaturation at temperatures above 8°C, and the degradation is not visually detectable (the solution may still appear clear). Temperature excursions above refrigeration range cause hydrolytic cleavage of the peptide backbone, rendering the compound biologically inactive. Using temperature-compromised tesamorelin wastes the injection (no GH response) and introduces risk of immune response to degraded peptide fragments. Peptide stability is the single most common protocol failure point our team observes. Invest in a compact medication cooler with temperature monitoring if refrigeration access is inconsistent.

Administer the dose as scheduled but expect reduced efficacy for that injection. Do not double-dose the next day to compensate. Post-meal insulin elevation suppresses growth hormone release through somatostatin pathway activation, reducing tesamorelin-stimulated GH pulse amplitude by 35–50% compared to fasted administration. One missed optimal window does not negate the protocol, but repeated post-meal dosing will significantly blunt visceral fat reduction outcomes. If meal timing makes fasted morning dosing impractical, the alternative is late-evening administration at least 3 hours post-dinner. Clinical data shows secondary GH pulses during early sleep stages that tesamorelin can amplify.